Beam Therapeutics Inc.
BEAM
$17.00
$0.382.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -163.27% | -0.60% | -10.00% | -2.29% | 472.36% |
| Total Depreciation and Amortization | 1.51% | 5.55% | 15.78% | 16.87% | 35.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.02% | 38.09% | 106.23% | 17.22% | 175.40% |
| Change in Net Operating Assets | 34.14% | -30.32% | -26.59% | 15.33% | -204.42% |
| Cash from Operations | -156.54% | 1.85% | 1.96% | 9.17% | 295.22% |
| Capital Expenditure | 17.25% | 80.16% | 87.88% | 59.48% | 56.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.10% | 1,251.40% | 453.55% | -262.15% | -16.44% |
| Cash from Investing | 28.73% | 341.43% | 310.93% | -310.07% | -13.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 49.75% | 82.66% | 70.65% | -7.12% |
| Issuance of Common Stock | -89.97% | -96.11% | -99.78% | -96.90% | 5.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -89.78% | -96.57% | -99.88% | -97.06% | 5.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.01% | 1.70% | 124.81% | -1,169.70% | 249.97% |